China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010
  • Feb/2011
  • Hard Copy
  • USD $2,100
  • Pages:80
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: JMH005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,300
In 2009, the consumption of oral hypoglyceimic agents (OHAs) in China increased by 15.1% to RMB9.81 billion, accounting for approximately 5% of the world’s total. At present, China is a country with the most populous victims of diabetes, numbering as high as 92 million. But the treatment rate of this disease in China is, generally speaking, less than 30%. Coupled with the comparatively low per capita treatment payment, which is no more than 3% of that in the US, China will witness a huge potential in the OHAS market.     

Among all the OHAS, patent medicines made by overseas pharmaceutical enterprises are hailed as “star products”. Many generic drugs exert little impact on patent medicines although they spring up. Meanwhile, foreign enterprises firmly control Chinese market by means of successful marketing strategy and product upgrading. In 2009, foreign enterprises occupied the top 5 by procurement value among the OHAS providers for China-based hospitals, making up as high as 60.8%. In particular, the ranking first Bayer, an acarbose producer, enjoyed a share of 29.4%. Of the top 10 enterprises by sales performance, Beijing Wanhui Double-Crane Pharmaceutical was the sole homegrown enterprise that produces gliquidone, with the market share no more than 3.7%.

Leading Enterprises and Market Share of OHAS Providers for China-based Hospitals, 2009
Source: China Pharmaceutical Industry Association; ResearchInChina

The report not only probes into the status quo and competition pattern of the market, drug use of hospitals, and development tendency of OHAS industry, but also analytically elaborates the market segments as well as the operation and prospect of leading manufacturers, including 7 foreign enterprises and joint ventures playing dominant position in OHAS traditional western medicine varieties and Chinese patent medicine market as well as four Chinese counterparts of certain scale.

OHAS Products Made in China and Market Share of Preventative Manufacturers in Hospital Medicine Market, 2009
Source: ResearchInChina

In addition, new OHAS varieties such as DDP-IV inhibitor and GLP-1 analog have been inflowing into Chinese market, including Januvia produced by Merck & Co Inc, and Onglyza by Bristol-Myers Squibb and AstraZeneca, which pose grave threat to traditional OHAS because of the good effect and little side-effect.

1. Overview of OHAS Industry
1.1 Definition
1.2 Classification

2. Status Quo and Prospect of Chinese OHAS Market
2.1 Status Quo of International Market
2.1.1 Market Size
2.1.2 Demand and Supply
2.2 Status Quo of Chinese Market
2.2.1 Market Size
2.2.2 Product Mix
2.3 Demand and Supply
2.4 Competition Pattern
2.5 Gross Margin of the Industry and Prices
2.6 Application of OHAS in Key Cities
2.6.1 Beijing
2.6.2 Shanghai
2.6.3 Guangzhou
2.6.4 Shenzhen
2.7 Policy Environment
2.8 Development Outlook
2.8.1 Huge Diabetic Population 
2.8.2 Improvement in Treatment Rate and Expense of Diabetic Patients
2.8.3 Strong Growth of New OHAS Varieties

3. Key Varieties of OHAS
3.1 Acarbose
3.2 Metformin
3.3 Repaglinide
3.4 Glimepiride
3.5 Gliclazide
3.6 Glipizide
3.7 Gliquidone
3.8 Rosiglitazone
3.9 DDP-IV Inhibitor 
3.10 GLP-1 Analog 

4. Advantageous Foreign Enterprises in China OHAS Industry
4.1 Bayer
4.1.1 Profile
4.1.2 Operation
4.1.3 Operation in China
4.2 Bristol-Myers Squibb
4.2.1 Profile
4.2.2 Operation
4.2.3 Shanghai Bristol-Myers Squibb
4.2.4 Developments
4.3 Novonordisk
4.3.1 Profile
4.3.2 Operation
4.3.3 Operation in China
4.3.4 Developments
4.4 Sanofi-Aventis
4.4.1 Profile
4.4.2 Operation
4.4.3 Operation in China
4.5 Servier
4.5.1 Profile
4.5.2 Servier (Tianjin) Pharmaceutical
4.6 Pfizer
4.6.1 Profile
4.6.2 Operation in China
4.7 GlaxoSmithKline
4.7.1 Profile
4.7.2 Operation
4.7.3 Operation in China

5. Local Advantageous Enterprises in China OHAS Industry
5.1 Huadong Medicine
5.1.1 Profile
5.1.2 Operation
5.1.3 Developments
5.2 Wanbang Biopharmaceuticals
5.2.1 Profile
5.2.2 Operation
5.3 Double-Crane Pharmaceutical
5.3.1 Profile
5.3.2 Operation
5.3.3 Developments
5.4 Guangzhou Pharmaceutical
5.4.1 Profile
5.4.2 Operation
Diabetes Types
Subdivided Varieties and Products of OHAS
Sales Value and YOY Growth of Anti-Diabetic Agents Worldwide, 2005-2009
Classification and Proportion of Anti-Diabetic Agents Worldwide, 2010
Population of Diabetic Suffers Worldwide, 2005-2009
Top 3 Countries with the Most Diabetic Victims, 2009
Consumption and Growth Rate of OHAS in China, 2007-2009
Ranking of Chinese Sample Hospitals by Purchasing Sum of OHAS Varieties, 2008 
Ranking of Chinese Sample Hospitals by Purchasing Sum of Leading OHAS Varieties, 2009
Ranking of Chinese Sample Hospitals by Import Value of Imported OHAS, 2009
Competitors and Proportion on OHAS Use Market of Chinese Sample Hospitals, 2009
OHAS Gross Margin of Partial Enterprises in China, 2009-2010
Prices of Partial OHAS Products of Golden Elephant Pharmacy, Feb. 2011
Ranking of Beijing Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
Varieties and Proportion of OHAS Used by Beijing Community Health Service Agency, 2009H1
Ranking of Shanghai Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
Ranking of Guangzhou Sample Hospitals by Purchasing Sum of Major OHAS Varieties, 2008-2009
OHAS Retail Market Scale in Shenzhen, 2008-2009H2
Proportion of OHAS Retail Market by Subclass in Shenzhen, 2009H2
Proportion of Various Enterprises in Shenzhen OHAS Retail Market, 2009H2
OHAS being Included in Catalogue of National Essential Drugs (2009)
OHAS being Included in Catalogue of National Basic Medical Insurance and Employment Injuries Insurance Drugs (2009) 
Diabetes Morbidity in China, 1980-2008
Average Treatment Expense of Diabetic Sufferers in China, 2009
OHAS Products and Representative Enterprises in China
Major Enterprises and Their Shares in China’s Acarbose Market, 2009 
Major Acarbose API & Preparation Manufacturers and Their Output, 2009
Competitors in China’s Voglibose Market and Market Shares, 2009
Competitors and Market Shares as Metformin Providers for China’s Leading Hospitals, 2009
Metformin API Producers and Their Output, 2009
Metformin Preparation Producers and Their Outputs, 2009
Imported & Homemade Repaglinide Purchased by China’s Sample Hospitals by Sum & Proportion, 2009
Major Enterprises and Proportion in Repaglinide Market, 2009
Imported & Homemade Glimepiride Purchased by China’s Sample Hospitals by Sum & Proportion, 2009
Major Enterprises and Proportion in Glimepiride Market, 2009
Glimepiride API Producers and Their Outputs in China, 2009
Competitors and Market Shares as Gliclazide Providers for China’s Leading Hospitals, 2009
Gliclazide Preparation Producers and Their Output, 2009
Hospitals’ Purchasing Sum of Glipizide/Melbine/Glibenclamide, 2005-2008
Competitors and Market Shares as Glipizide Providers for China’s Leading Hospitals, 2009
Glipizide Preparation Producers and Their Output, 2009
Major Enterprises and Proportion in Gliquidone Market of China, 2009
Gliquidone API & Preparation Producers and Their Output, 2009
Global Sales Value of Gliquidone Drugs, 2005-2009
Competitors and Market Shares as Gliquidone Providers for China’s Leading Hospitals, 2009
Pioglitazone Preparation Producers and Their Output, 2009
Sales Revenue of Januvia Worldwide, 2006-2009
Sales Revenue of Onglyza Produced by Shanghai Bristol-Myers Squibb, 2009-2010
Major DDP-IV Inhibitor Drugs Going Public
Leading GLP-1 Analogues 
Organization Structure of Bayer HealthCare AG
Global Sales Value of Bayer HealthCare Group, 2007-2010
Top 10 Products of Bayer Pharmaceuticals Division, Jan.-Sep., 2010
Global Sales Value and YoY Growth of Glucobay Produced by Bayer HealthCare AG, 2007-2010
Subsidiaries of Bayer HealthCare AG in China, as of 2009
Sales Value of Glucobay Produced by Bayer HealthCare AG in China, 2008-2009
Sales Value and YoY Growth of Bristol-Myers Squibb, 2007-2010
Sales Revenue Structure of Bristol-Myers Squibb, Jan.-Sep., 2010
Sales Revenue of Major Products Made by Bristol-Myers Squibb, 2007-2009  
Global Sales Revenue of Glucophage Made by Bristol-Myers Squibb, 2007-2008
Product Category of Bristol-Myers Squibb
Market Share of Glucophage Made by Shanghai Squibb Pharmaceuticals in China Melbine Market, 2008-2009
Dosage Form and Output of OHAS Preparation Made by Shanghai Squibb Pharmaceuticals, 2009
Dynamics in OHAS Field of Shanghai Squibb Pharmaceuticals, 2010
Primary Businesses and Products of Novonordisk, 2010H1
OHAS Products of Novonordisk, 2010
Operating Income and Net Income of Novonordisk, 2008-2010
Operating Income Structure of Diabetes Therapy Department of Novonordisk, Jan.-Sep., 2010
OHAS Sales Revenue and YoY Growth of Novonordisk in the World, 2007-2010 
Operating Income of Victoza Made by Novonordisk, 2010Q1-Q3
China-based Companies of Novonordisk and Their Businesses, 2009  
Sales Revenue and Market Share of Novonordisk-Made Repaglinide in China’s Sample Hospitals 
Key Developments of Novonordisk, 2010-2011
Diabetes Products of Sanofi-Aventis, 2009
Operating Income and Profit of Sanofi-Aventis, 2007-2010
Operating Income and YoY Growth of Glimepiride Produced by Sanofi-Aventis, 2007-2010
Glimepiride Operating Income of Sanofi-Aventis by Region, Jan.-Sep., 2010   
China-Based Companies under Sanofi-Aventis, 2010
Sales Revenue of Glimepiride in China’s Sample Hospitals and Market Share in Glilmepiride Market, 2008-2009
New Plants of Sanofi-Aventis Under Construction, as of 2010
Total Sales of Servier, 2009-2010
Registered Products Going Public in China of Servier
Market Share of Gliclazide Made by Servier (Tianjin) in China’s Sample Hospitals, 2008-2009
Businesses of Pfizer
Global Operating Income of Pfizer by Sector, 2007-2010
China-Based Manufacturers under Pfizer
Market Share of Glipizide Controlled-Rrelease Tablets Made by Pfizer in China’s Sample Hospitals, 2008-2009
Key Prescription Medicines and Treatment Fields of GlaxoSmithKline
Operating Income and Profit of GlaxoSmithKline, 2007-2010
Sales Revenue and YoY Growth of Avandia Products Made by GlaxoSmithKline, 2007-2010
Sales Revenue and YoY Growth of Avandia Products Made by GlaxoSmithKline, 2010Q1-Q3
China-Based Operating Companies under GlaxoSmithKline, as of 2010  
Sales Revenue and Market Share of Rosiglitazone Products Made by GlaxoSmithKline in China’s Sample Hospitals, 2008-2009
OHAS Products of Huadong Medicine
Operating Income and Total Profit of Huadong Medicine, 2007-2010
Operating Income and Net Income of Hangzhou Sino-US Huadong Medicines Group
Operating Income and Proportion of Acarbose Tablets & Pioglitazone Hydrochloride Tablets Made by Sino-US Huadong Medicines Group, 2009
Output and Export Volume of OHAS API Made by Sino-US Huadong Medicines Group, 2009
Dosage Form and Output of OHAS Preparation Made by Sino-US Huadong Medicines Group, 2009
Dynamics in Key Anti-Diabetes Agents Industry of Huadong Medicine, 2009-2010
Information about Jiangsu Wanbang Bio-pharm
Net Income of Primary Businesses of Jiangsu Wanbang Bio-pharm, 2007-2010
Sales Revenue and Market Share of Glimepiride Tablets in China’s Sample Hospitals, 2008-2009
Three Leading Medicines of Double-Crane Pharmaceutical
OHAS Products of Double-Crane Pharmaceutical, as of 2010
Operating Income and Total Profit of Double-Crane Pharmaceutical, 2007-2010
Sales Revenue of 3 Leading Products and Proportion in Operating Income of Double-Crane Pharmaceutical, 2009
Sales Revenue of Gliquidone Made by Double-Crane Pharmaceutical, 2008-2010
Dosage Form and Output of OHAS Preparation Made by Double-Crane Pharmaceutical, 2009
Major Chinese Patent Medicines and Treatment Fields of Guangzhou Pharmaceutical
Operating Income and Total Profit of Guangzhou Pharmaceutical, 2008-2010
Sales Value of Thirsty Releever Made by Guangzhou Pharmaceutical, 2007-2010

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号